Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progessive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs

Trial Profile

ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progessive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 May 2012 Additional lead trial centre and actual patient number (105) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top